UNSPSC 51191570: Xipamide

This classification denotes a diuretic with the molecular formula C15H15ClN2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4S9EY0NUEC, chemically known as 4-chloro-5-sulfamoyl-2,6-salicyloxylidide but generally known as xipamide, which bears US NIH Compound Identifier 26618. European Medicines Agency schedules Xipamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00116MIG.

UNSPSC 51191570 Xipamide (Commodity) shows minimal alignment with recent state and local procurement activity. The code nominally covers xipamide, a loop diuretic pharmaceutical, but the two recent solicitations tagged to it involve sodium bisulfite for water treatment operations and generic multi-source pharmaceuticals and over-the-counter products through a cooperative purchasing vehicle—neither of which represents the therapeutic or chemical scope the code specifies. State and local governments appear to source xipamide through broader pharmaceutical procurement frameworks rather than as a standalone commodity line, or the code receives limited standalone solicitation activity in the market captured here.

The City of Meriden (Connecticut) posted an IFB for sodium bisulfite supply to its Water Pollution Control Facility with a response date of July 29, 2026, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP to establish multi-vendor contracts for generic pharmaceuticals and OTC products with a response deadline of March 26, 2026 and an effective date of July 1, 2026. Neither solicitation addresses xipamide specifically, and the mismatch suggests either miscoding at the source, reliance on broader commodity classification for small-volume specialty pharmaceuticals, or dormancy of this code in current state and local procurement markets. Firms evaluating activity under this code should verify that recent opportunities actually require xipamide supply before committing resources to pursuit.